ArticleThe British journal of dermatology2019
Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study.
Article in The British journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 153 citations in OpenAlex.
- Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis.Inflammatory bowel diseases · 2026Pooled it
- Interventions for basal cell carcinoma of the skin.The Cochrane database of systematic reviews · 2020Pooled it
- Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies.BMJ (Clinical research ed.) · 2020Pooled it
- Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.Journal of Crohn's & colitis · 2024Trial
- Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).The British journal of dermatology · 2022Trial
- Comprehensive molecular characterization of cutaneous squamous cell carcinoma reveals determinants of metastatic progression.medRxiv : the preprint server for health sciences · 2026Article
- The Dutch cutaneous squamous cell carcinoma and metastasis (D-SQUAME) study: a nationwide discovery cohort and nationwide validation cohort with nested case-control designs for risk prediction modeling.European journal of epidemiology · 2026Article
- Spatially controlled induction and regression of basal cell carcinoma, visualized by serial imaging in young and old mice.JID innovations : skin science from molecules to population health · 2026Article
- Incidence and mortality of nonmelanoma skin cancer in Europe: current trends and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Automated data collection in cancer care: State of play among registries in the United Kingdom and Europe.Health information management : journal of the Health Information Management Association of Australia · 2026Article
- European Code Against Cancer, 5th edition - ultraviolet radiation, radon and cancer.Molecular oncology · 2026Review
- Advanced Cutaneous Squamous Cell Carcinoma: Biology, Immunotherapy, and Evolving Prognostic Factors.Biomedicines · 2025Review
- Longitudinal data on advanced cutaneous squamous cell carcinoma from the Dutch Keratinocyte Cancer Collaborative (DKCC): a nationwide real-world database study.The Lancet regional health. Europe · 2025Article
- Systematic Review of Line-Field Confocal Optical Coherence Tomography for Diagnosing Pre-Malignant and Malignant Keratinocytic Lesions: Optimising the Workflow.Diagnostics (Basel, Switzerland) · 2025Review
- Diagnostic Challenges and Influencing Factors in Non-Melanoma Skin Cancers: A Retrospective Analysis of Basal Cell Carcinoma and Squamous Cell Carcinoma Cases.Cancer reports (Hoboken, N.J.) · 2025Article
- The landscape of long noncoding RNA during cutaneous squamous cell carcinoma progression.The British journal of dermatology · 2025Article
- C5aR1 Promotes Invasion, Metastasis, and Poor Prognosis in Cutaneous Squamous Cell Carcinoma.The American journal of pathology · 2025Article
- Skin cancer screening practices of UK hairdressers and barbers for their customers: a preliminary study.Skin health and disease · 2025Article
- A Review of Neoadjuvant PD-1 Inhibitors in the Setting of Cutaneous Malignancies.The Journal of clinical and aesthetic dermatology · 2025Review
- Enhancing Diagnosis in Squamous Cell Carcinoma: Non-Invasive Imaging and Multimodal Approach.Diagnostics (Basel, Switzerland) · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 7 institutions in 3 countries.
Funding
Abstract
backgroundBasal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together known as keratinocyte cancers (KCs), are the commonest cancer in white ethnic populations. Recent improvements to registry data collection in England has allowed more accurate analysis of the epidemiology of BCC and cSCC and for the first time we are able to provide an accurate (representative) tumour burden for KC in the U.K.
objectivesTo estimate the incidence of BCC and cSCC in the U.K.
methodsA cohort of patients with KCs between 2013 and 2015 were identified using linkage to diagnostic codes derived from pathology reports collected into the national cancer registry. Data from England's cancer registry were combined with data from Scotland, Northern Ireland and Wales. European age-standardized incidence rates (EASRs) of the first BCC and cSCC per patient per annum (PPPA) were calculated.
resultsIn the U.K, the EASR of the first BCC and cSCC PPPA in 2013-15 were 285 and 77 per 100 000 person years, respectively (211 120 KCs total in 2015). The mean annual percentage increase was 5% between 2013 and 2015 for both BCC and cSCC. By counting the first KC PPPA, we include an additional 51% KCs compared with the previous reporting technique which counts only the first BCC and cSCC in a patient's lifetime, yet it represents a probable underestimation of 5-11% of the true tumour count.
conclusionsBased on an improved methodology, a more representative incidence of KC is presented, which is essential to healthcare planning and will lead to improved understanding of the epidemiology of KC. What's already known about this topic? Keratinocyte cancers (KCs) are the most common cancers affecting white ethnic populations. The incidence of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) is increasing worldwide including the U.K., most commonly in elderly male Caucasian patients. These cancers are traditionally substantially underreported and frequently excluded from national cancer statistics. What does this study add? Using improved data collection methods in England and validated tumour-reporting techniques, we report the most accurate BCC and cSCC incidence data for the U.K. ever published. Identifying the first BCC and cSCC per patient per annum, the incidence of BCC and cSCC in the U.K. (excluding Wales) was 285 and 77 per 100 000 person years, respectively, between 2013 and 2015, with more than 210 000 KCs in the U.K. in 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.